Silence Therapeutics plc: Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company")
Source: finanznachrichten.de
